{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:02:15Z","timestamp":1774969335155,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.clcc.2015.09.005","type":"journal-article","created":{"date-parts":[[2015,10,18]],"date-time":"2015-10-18T12:56:52Z","timestamp":1445173012000},"page":"91-94.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment"],"prefix":"10.1016","volume":"15","author":[{"given":"Eric","family":"Van Cutsem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Hocke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zohra","family":"Oum'Hamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matus","family":"Studeny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2015.09.005_bib1","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/annonc\/mdu260","article-title":"Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Van Cutsem","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2015.09.005_bib2","first-page":"252","article-title":"Cancer treatment and survivorship statistics, 2014","volume":"64","author":"DeSantis","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clcc.2015.09.005_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.critrevonc.2014.05.004","article-title":"What could nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?","volume":"92","author":"Capdevila","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clcc.2015.09.005_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2015.09.005_bib5","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/bjc.2011.85","article-title":"Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer","volume":"104","author":"Loupakis","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2015.09.005_bib6","unstructured":"National Comprehensive Cancer Network. NCCN guidelines: colon cancer, version 2.\u00a02015. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf. Accessed: March 10, 2015."},{"key":"10.1016\/j.clcc.2015.09.005_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2015.09.005_bib8","unstructured":"U.S. Food and Drug Administration. FDA approves ramucirumab in combination with FOLFIRI for the treatment of patients with metastatic colorectal cancer after first-line therapy. Available at: http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm444496.htm. Accessed: June 3,\u00a02015."},{"key":"10.1016\/j.clcc.2015.09.005_bib9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clcc.2015.09.005_bib10","unstructured":"Bayer Pharma AG. Stivarga\u00ae summary of product characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002573\/WC500149164.pdf. Accessed: May 26,\u00a02015."},{"key":"10.1016\/j.clcc.2015.09.005_bib11","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1186\/1471-2407-14-510","article-title":"Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis","volume":"14","author":"Mross","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clcc.2015.09.005_bib12","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.clcc.2015.09.005_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40265-014-0335-0","article-title":"Nintedanib: first global approval","volume":"75","author":"McCormack","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.clcc.2015.09.005_bib14","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1021\/jm501562a","article-title":"Nintedanib: from discovery to the clinic","volume":"58","author":"Roth","year":"2015","journal-title":"J\u00a0Med Chem"},{"issue":"suppl 2","key":"10.1016\/j.clcc.2015.09.005_bib15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0959-8049(11)70113-7","article-title":"A\u00a0phase l\/lI, open-label, randomised study of BIBF 1120 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 in patients with metastatic colorectal cancer","volume":"47","author":"Van Cutsem","year":"2011","journal-title":"Eur J Cancer"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002815001152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002815001152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:02:58Z","timestamp":1761519778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002815001152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1533002815001152"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2015.09.005","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2015.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}